Teva Pharmaceutical Industries (TEVA) Competitors $18.33 +0.29 (+1.59%) As of 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TEVA vs. GSK, TAK, ARGX, ONC, BNTX, INSM, SMMT, GMAB, VTRS, and RDYShould you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Teva Pharmaceutical Industries vs. Its Competitors GSK Takeda Pharmaceutical argenex BeOne Medicines BioNTech Insmed Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories Teva Pharmaceutical Industries (NYSE:TEVA) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Do analysts prefer TEVA or GSK? Teva Pharmaceutical Industries currently has a consensus target price of $24.71, indicating a potential upside of 34.85%. GSK has a consensus target price of $37.38, indicating a potential downside of 5.30%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25GSK 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Do institutionals and insiders believe in TEVA or GSK? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TEVA or GSK more profitable? GSK has a net margin of 10.81% compared to Teva Pharmaceutical Industries' net margin of -0.95%. GSK's return on equity of 49.22% beat Teva Pharmaceutical Industries' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% GSK 10.81%49.22%11.31% Does the media prefer TEVA or GSK? In the previous week, GSK had 14 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 34 mentions for GSK and 20 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.27 beat GSK's score of 0.53 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 13 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GSK 17 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk and volatility, TEVA or GSK? Teva Pharmaceutical Industries has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Which has stronger earnings and valuation, TEVA or GSK? GSK has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.27-$1.64B-$0.16-114.54GSK$40.10B2.00$3.29B$2.1618.27 SummaryGSK beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks. Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TEVA vs. The Competition Export to ExcelMetricTeva Pharmaceutical IndustriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$21.02B$4.24B$5.75B$21.26BDividend YieldN/A1.29%3.95%3.51%P/E Ratio-114.5311.1631.4529.29Price / Sales1.2715.08428.1968.14Price / Cash5.377.1037.7523.86Price / Book3.084.8110.535.37Net Income-$1.64B-$109.62M$3.27B$996.52M7 Day Performance-0.75%-1.18%1.04%0.39%1 Month Performance11.04%20.31%5.74%3.46%1 Year Performance-2.15%32.72%50.88%12.08% Teva Pharmaceutical Industries Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TEVATeva Pharmaceutical Industries3.341 of 5 stars$18.33+1.6%$24.71+34.9%-2.9%$21.02B$16.54B-114.5336,800News CoveragePositive NewsGSKGSK2.5735 of 5 stars$39.05-0.8%$37.38-4.3%-10.2%$79.57B$40.10B18.0868,629Trending NewsDividend CutTAKTakeda Pharmaceutical1.2901 of 5 stars$15.18+1.2%N/A+0.0%$48.31B$30.09B50.6147,455ARGXargenex3.0929 of 5 stars$661.32+1.1%$746.81+12.9%+35.7%$40.47B$2.25B33.911,599News CoverageAnalyst ForecastAnalyst RevisionONCBeOne Medicines0.7462 of 5 stars$319.32-0.6%$330.89+3.6%N/A$35.00B$3.81B-184.5811,000Gap UpBNTXBioNTech2.9212 of 5 stars$112.55-0.9%$135.80+20.7%+15.6%$27.06B$2.98B-70.346,772Positive NewsINSMInsmed3.7968 of 5 stars$127.27-0.4%$129.57+1.8%+76.4%$26.90B$363.71M-22.291,271Positive NewsSMMTSummit Therapeutics2.2482 of 5 stars$26.28-1.5%$35.00+33.2%+86.1%$19.52BN/A-26.02110Positive NewsAnalyst ForecastAnalyst RevisionGMABGenmab A/S3.5807 of 5 stars$23.42+0.5%$37.60+60.5%-9.4%$15.02B$3.12B11.772,682News CoverageVTRSViatris1.9575 of 5 stars$10.63+0.2%$10.40-2.2%-12.5%$12.39B$14.74B-3.6732,000RDYDr. Reddy's Laboratories2.9388 of 5 stars$14.26+0.2%$16.95+18.9%-14.5%$11.90B$3.81B21.6027,811News Coverage Related Companies and Tools Related Companies GSK Alternatives TAK Alternatives ARGX Alternatives ONC Alternatives BNTX Alternatives INSM Alternatives SMMT Alternatives GMAB Alternatives VTRS Alternatives RDY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:TEVA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access